Annovis Bio prices 1.67M shares at $2.05 in registered direct offering

Annovis Bio (ANVS) entered into definitive agreements, with the participation of Michael Hoffman, the Chairman of the Company’s board of directors, and Dr. Maria Maccecchini, CEO, for the purchase of an aggregate of 1,670,732 shares of its common stock at a purchase price of $2.05 per share, which was the closing price of the common stock on NYSE on October 24, 2025, in a registered direct offering. The closing of the offering is expected to occur on or about October 28, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The aggregate gross proceeds to the Company from the offering are expected to be approximately $3.4M, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering toward working capital and general corporate purposes.